# DEC003M in Prostate Cancer

> **NCT07657806** · PHASE1 · RECRUITING · sponsor: **Hangzhou DAC Biotechnology Co., Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- Advanced Prostate Cancer

## Interventions

- **DRUG:** DEC003M

## Key facts

- **NCT ID:** NCT07657806
- **Lead sponsor:** Hangzhou DAC Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-19
- **Primary completion:** 2029-03-31
- **Final completion:** 2031-05-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07657806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07657806, "DEC003M in Prostate Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07657806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*